UBS Group
PRPH

UBS Group’s ProPhase Labs PRPH Stock Holding History

UBS Group’s Portfolio PRPH Stock Details PRPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,056
Closed -$1.37K – 11016
2025
Q4 		$1.37K Buy
3,056
+1,082
+55% +$3.04K ﹤0.01% 9608
2025
Q3 		$9.04K Sell
1,974
-3,793
-66% -$14.7K ﹤0.01% 8626
2025
Q2 		$22.5K Buy
5,767
+4,857
+534% +$16.2K ﹤0.01% 8353
2025
Q1 		$3.67K Buy
910
+587
+182% +$2.69K ﹤0.01% 9190
2024
Q4 		$2.44K Sell
323
-728
-69% -$10.2K ﹤0.01% 9049
2024
Q3 		$25.4K Buy
+1,051
New +$29.6K ﹤0.01% 7231
2024
Q2 		– Sell
-332
Closed -$21.5K – 9963
2024
Q1 		$21.5K Buy
+332
New +$16.8K ﹤0.01% 6897
2023
Q2 		– Sell
-475
Closed -$36.2K – 9473
2023
Q1 		$36.2K Sell
475
-1,179
-71% -$95K ﹤0.01% 6665
2022
Q4 		$159K Sell
1,654
-892
-35% -$96.4K ﹤0.01% 5668
2022
Q3 		$287K Buy
2,546
+2,402
+1,668% +$279K ﹤0.01% 4809
2022
Q2 		$18K Sell
144
-6
-4% -$527 ﹤0.01% 7026
2022
Q1 		$11K Sell
150
-37
-20% -$2.57K ﹤0.01% 8315
2021
Q4 		$13K Buy
+187
New +$11.6K ﹤0.01% 8467
2021
Q3 		– Sell
-904
Closed -$56K – 9959
2021
Q2 		$56K Buy
904
+886
+4,922% +$49.8K ﹤0.01% 6327
2021
Q1 		$1K Sell
18
-94
-84% -$9.02K ﹤0.01% 8787
2020
Q4 		$11K Sell
112
-398
-78% -$33.4K ﹤0.01% 7415
2020
Q3 		$18K Sell
510
-183
-26% -$4.39K ﹤0.01% 6397
2020
Q2 		$10K Sell
693
-763
-52% -$12.6K ﹤0.01% 7020
2020
Q1 		$28K Buy
1,456
+109
+8% +$2.04K ﹤0.01% 6274
2019
Q4 		$26K Buy
1,347
+13
+1% +$254 ﹤0.01% 6735
2019
Q3 		$26K Sell
1,334
-354
-21% -$7.03K ﹤0.01% 6576
2019
Q2 		$36K Sell
1,688
-252
-13% -$7.42K ﹤0.01% 6190
2019
Q1 		$58K Sell
1,940
-324
-14% -$9.98K ﹤0.01% 5443
2018
Q4 		$71K Sell
2,264
-66
-3% -$2.01K ﹤0.01% 5825
2018
Q3 		$70K Sell
2,330
-241
-9% -$7.27K ﹤0.01% 5884
2018
Q2 		$84K Buy
2,571
+862
+50% +$28.5K ﹤0.01% 5575
2018
Q1 		$51K Sell
1,709
-1
-0.1% -$25 ﹤0.01% 5699
2017
Q4 		$37K Sell
1,710
-500
-23% -$10.9K ﹤0.01% 6085
2017
Q3 		$48K Buy
2,210
+1,097
+99% +$23.6K ﹤0.01% 5822
2017
Q2 		$23K Buy
1,113
+53
+5% +$1.06K ﹤0.01% 6196
2017
Q1 		$24K Sell
1,060
-416
-28% -$8.44K ﹤0.01% 6018
2016
Q4 		$29K Buy
1,476
+45
+3% +$909 ﹤0.01% 6261
2016
Q3 		$28K Buy
1,431
+371
+35% +$6.37K ﹤0.01% 6004
2016
Q2 		$14K Sell
1,060
-298
-22% -$4.02K ﹤0.01% 6573
2016
Q1 		$19K Sell
1,358
-672
-33% -$8.41K ﹤0.01% 6249
2015
Q4 		$30K Sell
2,030
-97
-5% -$1.4K ﹤0.01% 6328
2015
Q3 		$34K Buy
2,127
+77
+4% +$1.16K ﹤0.01% 6178
2015
Q2 		$28K Buy
2,050
+552
+37% +$7.4K ﹤0.01% 6556
2015
Q1 		$19K Buy
1,498
+98
+7% +$1.44K ﹤0.01% 7043
2014
Q4 		$20K Buy
+1,400
New +$19.4K ﹤0.01% 7678

Other funds holding PRPH

CA
CoreCap Advisors Southfield, Michigan $3.39B AUM 31.21% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

UBS Group's PRPH Position: Q1 2026 in Review

UBS Group sold out of ProPhase Labs (PRPH) in Q1 2026, closing a stake of 3,056 shares — an estimated $1.37K sold.

UBS Group first reported a position in PRPH in Q4 2014 and held it in 40 quarters. The position peaked at $287K in Q3 2022. 2 funds tracked by Wall St. Rank hold PRPH as of Q1 2026.

  • UBS Group reported no remaining ProPhase Labs position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 3,056 ProPhase Labs shares in Q1 2026, an estimated $1.37K.
  • UBS Group first reported a position in ProPhase Labs in Q4 2014 and held it in 40 quarters.
  • UBS Group's ProPhase Labs position peaked at $287K in Q3 2022.
  • 2 funds tracked by Wall St. Rank held ProPhase Labs as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.